收藏切换
Pharmacokinetics and Bioequivalence of Tofacitinib Citrate Extended-release Tablets in Healthy Volunteers
收藏切换
Shiyun CHEN1, 2, Yonghao GAO3, Yong HE2, 3, Yanying YU2, 3, *
Chinese Journal of Pharmaceuticals | 2026, 57(1) : 81 - 86
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2026, 57(1): 81-86
• Paper •
Pharmacokinetics and Bioequivalence of Tofacitinib Citrate Extended-release Tablets in Healthy Volunteers
Full
Shiyun CHEN1, 2, Yonghao GAO3, Yong HE2, 3, Yanying YU2, 3, *
Affiliations
  • 1.Analytical & Testing Center, Hefei University, Hefei 230601
  • 2.Anhui Province Key Lab. of Pharmaceutical Preparation Technology and Application, Hefei 230012
  • 3.Hefei Huafang Pharmaceutical Science & Technology Co., Ltd., Hefei 230088
Published: 2026-01-10 doi: 10.16522/j.cnki.cjph.2026.01.008
Outline
收藏切换

A randomized, two-period cross-over design was conducted to evaluate the pharmacokinetics and bioequivalence of two brands of tofacitinib citrate extended-release tablets in healthy volunteers. Following a single oral dose of the test(T) and reference(R) preparations, plasma concentrations of tofacitinib at different time points were measured using a validated LC-MS/MS method. The main pharmacokinetic parameters of T and R preparations were calculated and listed as follows: under fasting conditions, cmax were (53.84±11.48) and (55.54±13.22)ng/mL, AUC0→t were (379.75±79.20) and (376.76±90.97)ng·h·mL–1,AUC0→∞ were (383.30±79.06) and (387.94±82.67)ng·h·mL–1.Under fed conditions, cmax were (72.09±16.39) and (69.49±16.52)ng/mL,AUC0→t were (385.10±85.75) and (386.83±89.69)ng·h·mL–1,AUC0→∞ were (391.76±87.17) and (391.29±96.47)ng·h·mL–1. The results showed that under fasting and fed conditions, there were no significant differences in above parameters between T and R preparations(P>0.05). The geometric mean ratios of the main pharmacokinetic parameters for T and R preparations both fell within the 90% confidence interval of 80.00% - 125.00%. No serious adverse events were observed during the study, all reported adverse events were Grade 1 in severity. These results indicated that the T and R preparations were bioequivalent in Chinese healthy volunteers with acceptable safety and tolerability, supporting the potential for domestic substitution of tofacitinib citrate extended-release tablets.

tofacitinib citrate extended-release tablet  /  rheumatoid arthritis  /  LC-MS/MS method  /  pharmacokinetics  /  bioequivalence
陈仕云, 高永好, 何勇, 于艳英. 枸橼酸托法替布缓释片在健康志愿者体内的药动学和生物等效性. 中国医药工业杂志, 2026 , 57 (1) : 81 -86 . DOI: 10.16522/j.cnki.cjph.2026.01.008
Shiyun CHEN, Yonghao GAO, Yong HE, Yanying YU. Pharmacokinetics and Bioequivalence of Tofacitinib Citrate Extended-release Tablets in Healthy Volunteers[J]. Chinese Journal of Pharmaceuticals, 2026 , 57 (1) : 81 -86 . DOI: 10.16522/j.cnki.cjph.2026.01.008
Year 2026 volume 57 Issue 1
201
66
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2026.01.008
  • Receive Date:2025-04-13
  • Online Date:2026-11-05
  • Published:2026-01-10
Article Data
Affiliations
History
  • Received:2025-04-13
Funding
Affiliations
    1.Analytical & Testing Center, Hefei University, Hefei 230601
    2.Anhui Province Key Lab. of Pharmaceutical Preparation Technology and Application, Hefei 230012
    3.Hefei Huafang Pharmaceutical Science & Technology Co., Ltd., Hefei 230088
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2026.01.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT